ReviewInternational journal of molecular sciences2020
Human Cell Modeling for Cardiovascular Diseases.
Review in International journal of molecular sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 37 citations in OpenAlex.
- Long Non-Coding Ribonucleic Acid Taurine Up-Regulated Gene 1 Accelerates Ventricular Septal Defect Formation in Children.Brazilian journal of cardiovascular surgery · 2026Article
- Article
- Engineering cardiac regeneration using stem cells: Cellular sources, differentiation signatures, targeted delivery, and functional recovery.Regenerative therapy · 2026Review
- Transcriptomic and epigenomic profiling datasets of murine HL-1 cardiomyocytes.Data in brief · 2026Article
- Computational Modeling Meets 3D Bioprinting: Emerging Synergies in Cardiovascular Disease Modeling.Advanced healthcare materials · 2026Review
- Reimagining human-centric drug development with new approach methodologies.Science (New York, N.Y.) · 2026Review
- Amyloid β Instigates Cardiac Neurotrophic Signaling Impairment, Driving Alzheimer's Associated Heart Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Evidence of Cardiotoxic Immune Activation by Triple Immune Checkpoint Blockade: A Translational Alert for Clinical Surveillance in Patients With Cancer.Journal of cardiovascular pharmacology · 2026Article
- Special Issue "New Trends in Diabetes, Hypertension and Cardiovascular Diseases: 3rd Edition".International journal of molecular sciences · 2025Article
- Stimuli-responsive hybrid materials for 4DMaterials today. Bio · 2025Review
- Key parameters for designing robust 2D and 3D spheroid models forBioengineering & translational medicine · 2025Review
- Catecholaminergic Polymorphic Ventricular Tachycardia: Advancing From Molecular Insights to Preclinical Models.Journal of the American Heart Association · 2025Review
- Heart-on-a-chip: a revolutionary organ-on-chip platform for cardiovascular disease modeling.Journal of translational medicine · 2025Review
- Cardiovascular diseases in the elderly: possibilities for modulating autophagy using non-coding RNAs.Frontiers in cell and developmental biology · 2025Review
- Evaluation of natural products bioactivity in cardiovascular diseases utilizing zebrafish models: a comprehensive review.Frontiers in pharmacology · 2025Review
- Trimethylamine N-oxide (TMAO) acutely alters ionic currents but does not increase cardiac cell death.Frontiers in physiology · 2025Article
- Advancing 3D Engineered In Vitro Models for Heart Failure Research: Key Features and Considerations.Bioengineering (Basel, Switzerland) · 2024Review
- Article
- The Role of BAG3 Protein Interactions in Cardiomyopathies.International journal of molecular sciences · 2024Article
- Progress in preclinical research on induced pluripotent stem cell therapy for acute myocardial infarction.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
The availability of appropriate and reliable in vitro cell models recapitulating human cardiovascular diseases has been the aim of numerous researchers, in order to retrace pathologic phenotypes, elucidate molecular mechanisms, and discover therapies using simple and reproducible techniques. In the past years, several human cell types have been utilized for these goals, including heterologous systems, cardiovascular and non-cardiovascular primary cells, and embryonic stem cells. The introduction of induced pluripotent stem cells and their differentiation potential brought new prospects for large-scale cardiovascular experiments, bypassing ethical concerns of embryonic stem cells and providing an advanced tool for disease modeling, diagnosis, and therapy. Each model has its advantages and disadvantages in terms of accessibility, maintenance, throughput, physiological relevance, recapitulation of the disease. A higher level of complexity in diseases modeling has been achieved with multicellular co-cultures. Furthermore, the important progresses reached by bioengineering during the last years, together with the opportunities given by pluripotent stem cells, have allowed the generation of increasingly advanced in vitro three-dimensional tissue-like constructs mimicking in vivo physiology. This review provides an overview of the main cell models used in cardiovascular research, highlighting the pros and cons of each, and describing examples of practical applications in disease modeling.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.